ADAG

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Adagene Inc

NASDAQ | ADAG

2.06

USD

+$0.00

(

+0.00%

)

At Close (As of Dec 3, 2025)

$84.84M

Market Cap

-

P/E Ratio

-0.64

EPS

$3.16

52 Week High

$1.30

52 Week Low

HEALTHCARE

Sector

ADAG Chart

Recent Chart
Price Action

ADAG Technicals

Tags:

ADAG Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$823K
Total Revenue $103K
Cost Of Revenue $926K
Costof Goods And Services Sold $926K
Operating Income -$36M
Selling General And Administrative $7.3M
Research And Development $29M
Operating Expenses $36M
Investment Income Net -
Net Interest Income $2.9M
Interest Income $3.8M
Interest Expense $852K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $926K
Income Before Tax -$33M
Income Tax Expense -$18K
Interest And Debt Expense -
Net Income From Continuing Operations -$33M
Comprehensive Income Net Of Tax -
Ebit -$33M
Ebitda -$32M
Net Income -$33M

Revenue & Profitability

Earnings Performance

ADAG Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $89M
Total Current Assets $88M
Cash And Cash Equivalents At Carrying Value $85M
Cash And Short Term Investments $85M
Inventory -
Current Net Receivables $8.3K
Total Non Current Assets $1.5M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $2.6M
Other Non Current Assets -
Total Liabilities $39M
Total Current Liabilities $38M
Current Accounts Payable $4.2M
Deferred Revenue -
Current Debt -
Short Term Debt $18M
Total Non Current Liabilities $560K
Capital Lease Obligations $284K
Long Term Debt $417K
Current Long Term Debt $18M
Long Term Debt Noncurrent -
Short Long Term Debt Total $18M
Other Current Liabilities $16M
Other Non Current Liabilities -
Total Shareholder Equity $51M
Treasury Stock -
Retained Earnings -$311M
Common Stock $5.9K
Common Stock Shares Outstanding $36M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$30M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $926K
Capital Expenditures $34K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $1.1M
Cashflow From Financing $3.8M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity $0
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$33M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$823K
Total Revenue $103K
Cost Of Revenue $926K
Costof Goods And Services Sold $926K
Operating Income -$36M
Selling General And Administrative $7.3M
Research And Development $29M
Operating Expenses $36M
Investment Income Net -
Net Interest Income $2.9M
Interest Income $3.8M
Interest Expense $852K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $926K
Income Before Tax -$33M
Income Tax Expense -$18K
Interest And Debt Expense -
Net Income From Continuing Operations -$33M
Comprehensive Income Net Of Tax -
Ebit -$33M
Ebitda -$32M
Net Income -$33M

ADAG News

ADAG Profile

Adagene Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Adagene Inc. is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, focusing on the innovative development of monoclonal antibody therapies for oncology. Leveraging its proprietary technologies, Adagene is pioneering next-generation antibody drug candidates aimed at improving efficacy and reducing side effects in cancer treatment. With a robust pipeline of drug candidates, the company is well-positioned to make significant advancements in the biopharmaceutical landscape, targeting unmet medical needs in cancer care.

LPTX
+368.57%
$2.05
PAVS
-38.29%
$0.03
VRAX
+75.10%
$0.68
IRBT
+73.84%
$3.39
IXHL
+12.68%
$0.44
VHAI
-33.33%
$0.00
NVDA
-1.03%
$179.59
KITT
+115.88%
$1.56
ONDS
+10.53%
$8.92
PLUG
+5.68%
$2.23
NIO
-4.77%
$4.79
TSLA
+4.07%
$446.74
RR
+18.53%
$4.22
INTC
+0.66%
$43.76
IPG
-1.95%
$24.57
ASST
+1.44%
$1.05
BYND
-3.10%
$1.25
BITF
+0.32%
$3.11
VALE
+3.18%
$13.30
AXDX
-61.36%
$0.03
AAL
+2.24%
$14.56
IREN
+6.90%
$43.96
CAPR
+371.06%
$29.96
BMNR
+5.48%
$33.66
NFLX
-4.92%
$103.96
MRVL
+7.86%
$100.20
SOFI
-1.49%
$29.07
PFE
+1.67%
$25.57
ADAP
-15.14%
$0.05
BBD
-2.35%
$3.58
ACHR
+9.15%
$8.35
DNN
+4.24%
$2.70
F
+1.00%
$13.09
INHD
-6.65%
$0.13
AAPL
-0.71%
$284.15
SOND
-23.45%
$0.12
MARA
+4.70%
$12.47
KVUE
+0.65%
$16.97
BMNU
+10.08%
$8.08
GOOGL
+1.20%
$319.63
RMBL
+60.50%
$3.21
QBTS
+11.46%
$25.08
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
BAC
+1.69%
$54.09
BTBT
+4.01%
$2.33
AMZN
-0.87%
$232.38
CLSK
+5.68%
$14.49
SRM
+53.27%
$10.30
GRAB
+0.19%
$5.27
RGTI
+9.04%
$26.04
MSFT
-2.50%
$477.73
AEO
+15.07%
$23.97
PCG
-0.58%
$15.23
RIG
+3.24%
$4.45
CIFR
+5.61%
$18.63
RIVN
+1.74%
$17.53
GOOG
+1.45%
$320.62
PLTR
+3.15%
$176.08
WULF
+1.47%
$14.43
WLGS
-5.57%
$0.04
PLTD
-3.30%
$6.73
AMD
+1.09%
$217.60
MTSR
-0.35%
$70.50
HBAN
+2.89%
$17.04
T
-0.78%
$25.32
BMY
+5.61%
$50.96
MSTR
+3.89%
$188.39
BTG
+1.58%
$4.50
SMR
+6.50%
$20.14
SNAP
+0.52%
$7.66
HOOD
+6.10%
$133.64
PYPL
-2.63%
$61.24
WMT
+1.77%
$114.41
AUR
+13.03%
$4.51
ASBP
-10.81%
$0.08
CHR
-6.96%
$0.04
AFMD
-34.94%
$0.18
NOK
+1.13%
$6.26
FCX
+3.63%
$44.53
MCHP
+12.16%
$63.61
WBD
+0.16%
$24.57
IMRN
-10.91%
$1.55
CMG
-0.61%
$33.93
GTLB
-12.77%
$37.83
PMAX
+25.55%
$2.85
ITUB
+0.38%
$7.92
M
-1.10%
$22.46
CMND
-14.27%
$0.11
PSTG
-27.29%
$68.87
UBER
+3.55%
$90.68
CRCL
+11.42%
$86.29
APLD
+4.67%
$29.36
TWOH
0.00%
$0.00
CGC
+4.50%
$1.16
AVGO
-0.25%
$380.61
AMCR
+0.71%
$8.46
SOUN
+4.99%
$11.78
VZ
+0.14%
$40.67
CRWV
+4.37%
$79.36
LPTX
+368.57%
$2.05
PAVS
-38.29%
$0.03
VRAX
+75.10%
$0.68
IRBT
+73.84%
$3.39
IXHL
+12.68%
$0.44
VHAI
-33.33%
$0.00
NVDA
-1.03%
$179.59
KITT
+115.88%
$1.56
ONDS
+10.53%
$8.92
PLUG
+5.68%
$2.23
NIO
-4.77%
$4.79
TSLA
+4.07%
$446.74
RR
+18.53%
$4.22
INTC
+0.66%
$43.76
IPG
-1.95%
$24.57
ASST
+1.44%
$1.05
BYND
-3.10%
$1.25
BITF
+0.32%
$3.11
VALE
+3.18%
$13.30
AXDX
-61.36%
$0.03
AAL
+2.24%
$14.56
IREN
+6.90%
$43.96
CAPR
+371.06%
$29.96
BMNR
+5.48%
$33.66
NFLX
-4.92%
$103.96
MRVL
+7.86%
$100.20
SOFI
-1.49%
$29.07
PFE
+1.67%
$25.57
ADAP
-15.14%
$0.05
BBD
-2.35%
$3.58
ACHR
+9.15%
$8.35
DNN
+4.24%
$2.70
F
+1.00%
$13.09
INHD
-6.65%
$0.13
AAPL
-0.71%
$284.15
SOND
-23.45%
$0.12
MARA
+4.70%
$12.47
KVUE
+0.65%
$16.97
BMNU
+10.08%
$8.08
GOOGL
+1.20%
$319.63
RMBL
+60.50%
$3.21
QBTS
+11.46%
$25.08
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
BAC
+1.69%
$54.09
BTBT
+4.01%
$2.33
AMZN
-0.87%
$232.38
CLSK
+5.68%
$14.49
SRM
+53.27%
$10.30
GRAB
+0.19%
$5.27
RGTI
+9.04%
$26.04
MSFT
-2.50%
$477.73
AEO
+15.07%
$23.97
PCG
-0.58%
$15.23
RIG
+3.24%
$4.45
CIFR
+5.61%
$18.63
RIVN
+1.74%
$17.53
GOOG
+1.45%
$320.62
PLTR
+3.15%
$176.08
WULF
+1.47%
$14.43
WLGS
-5.57%
$0.04
PLTD
-3.30%
$6.73
AMD
+1.09%
$217.60
MTSR
-0.35%
$70.50
HBAN
+2.89%
$17.04
T
-0.78%
$25.32
BMY
+5.61%
$50.96
MSTR
+3.89%
$188.39
BTG
+1.58%
$4.50
SMR
+6.50%
$20.14
SNAP
+0.52%
$7.66
HOOD
+6.10%
$133.64
PYPL
-2.63%
$61.24
WMT
+1.77%
$114.41
AUR
+13.03%
$4.51
ASBP
-10.81%
$0.08
CHR
-6.96%
$0.04
AFMD
-34.94%
$0.18
NOK
+1.13%
$6.26
FCX
+3.63%
$44.53
MCHP
+12.16%
$63.61
WBD
+0.16%
$24.57
IMRN
-10.91%
$1.55
CMG
-0.61%
$33.93
GTLB
-12.77%
$37.83
PMAX
+25.55%
$2.85
ITUB
+0.38%
$7.92
M
-1.10%
$22.46
CMND
-14.27%
$0.11
PSTG
-27.29%
$68.87
UBER
+3.55%
$90.68
CRCL
+11.42%
$86.29
APLD
+4.67%
$29.36
TWOH
0.00%
$0.00
CGC
+4.50%
$1.16
AVGO
-0.25%
$380.61
AMCR
+0.71%
$8.46
SOUN
+4.99%
$11.78
VZ
+0.14%
$40.67
CRWV
+4.37%
$79.36
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.